bwge2021 has ended

Create Your Own Event

bwge2021

16:05 CET

I07: Ultraproactive therapeutic drug monitoring based on point-of-care testing of infliximab is not superior to reactive drug monitoring in patients with inflammatory bowel disease: 1 year results of a pragmatic... TBAPeter BOSSUYT • Sophie Claeys • Soetkin D'Haens • Eveline Hoefkens • Beatrijs Strubbe • Denis Marichal • Lieven Pouillon • Harald Peeters

16:10 CET

I08: Quality improvement by benchmarking of a core outcome indicator set in inflammatory bowel disease: a multicentric feasibility study. TBAPeter BOSSUYT • Didier Baert • Filip Baert • Eveline Hoefkens • Inge Huys • Nikki Lembrechts • Evva Jonckere • Pieter Dewint • Lieven Pouillon

16:15 CET

Q&A TBA

16:20 CET

I09: Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unit TBAGoedele Dewitte • Jeroen Geldof • Marie Truyens • Triana Lobaton

16:25 CET

I10: One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis TBABram Verstockt • Dahham Alsoud • An Outtier • João Sabino • Séverine Vermeire • Gert De Hertogh • Marc Ferrante

16:30 CET

Q&A TBA

16:35 CET

I11: Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study TBASéverine Vermeire • Brian G. Feagan • Edward V. Loftus Jr • Silvio Danese • William J. Sandborn • Tim Ritter • Rajiv Mehta • Ursula Seidler • Frank Seibold • Ian Beales • Hyo Jong Kim Jong Kim • John McNally • Chohee Yun • Sally Zhao • Xiaopeng Liu • Chantal Tasset • Robin Besuyen • Mamoru Watanabe • Stefan Schreiber • Gerhard Rogler • Toshifumi Hibi • Laurent Peyrin-Biroulet

16:40 CET

I12: Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately-Severely Active Ulcerative Colitis: Phase 2b/3 SELECTION Study TBALaurent Peyrin-Biroulet • Edward V. Loftus Jr • Silvio Danese • William J. Sandborn • Ronald Fogel • Sandeep Nijhawan • Radoslaw Kempinski • Rafal Filip • Ihor Hospodarsky • John McNally • Chohee Yun • Sally Zhao • Xiaopeng Liu • Chantal Tasset • Robin Besuyen • Mamoru Watanabe • Stefan Schreiber • Gerhard Rogler • Toshifumi Hibi • Brian G. Feagan • Severine Vermeire

16:45 CET

Q&A TBA

16:50 CET

Invited Lecture: Intestinal Ultrasound in IBD: what is the Current Evidence? TBAChristian Maaser

17:05 CET

Invited Lecture: Stricturoplasy, is there still any Place for Resections? TBAAndré d’Hoore

17:20 CET

Invited Lecture: Adolescents and Young Adults with Crohn’s Disease: Health Literacy and Transition of Care. TBAEls Van De Vijver • Gigi Veereman

17:35 CET

Q&A TBA

17:55 CET

K01: First experiences with Modulife® in inducing remission in pediatric Crohn patients in Belgium. TBAEveline Snoeck • Els Van De Vijver • Ann Van Gils • Nicolette Moes • Ilse Hoffman • Bruno HAUSER • Gigi Veereman • Ruth De Bruyne • Stephanie Van Biervliet • Myriam Van Winckel • Saskia Vande Velde

18:00 CET

I13: Positioning strictureplasty in the treatment of extensive Crohn’s disease ileitis. A comparative study with ileocecal resection. TBAGabriele Bislenghi • Steffen Fieuws • Albert Wolthuis • Dirk Vanbeckevoort • Marc Ferrante • André D'Hoore • Joao Sabino • Severine Vermeire

18:05 CET

Q&A TBA

18:10 CET

I14: Evaluation of trough level and disease activity after switch from adalimumab originator (Humira®) to biosimilar (Imraldi®) in patients with inflammatory bowel disease: 6 month interim analysis of the SafE-OrBi... TBANele Deprez • Thomas De Somer • Didier Baert • Mieke Deceuninck • Inge Huys • Veerle Mattens • An Sterckx • Stijn Vanden Branden • Erik Vanderstraeten • Jo Vandervoort • Nina Van Heddegem • Pieter Dewint

18:15 CET

I15: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator TBAThomas De Somer • Nele Deprez • Didier Baert • Mieke Deceuninck • Inge Huys • Veerle Mattens • An Sterckx • Stijn Vanden Branden • Erik Vanderstraeten • Jo Vandervoort • Nina Van Heddegem • Pieter Dewint

18:20 CET

Q&A TBA

18:25 CET

Award Ceremony, Closing and Remarks TBA

18:30 CET

General Assembly of the Scientific Group? TBA